Research Activity – Page 51

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

1 year ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.

NS Pharma’s Duchenne Muscular Dystrophy Therapy Viltepso Fails Confirmatory Trial

1 year ago talkbio0Tagged Approved, Clinical Research, Confirmatory Trial, Duchenne, Muscular Dystrophy, nanosecond, Pharma, Phase III, RACER53, United States Food and Drug Administration, Viltepso

NS Pharma, Viltepso, Duchenne Muscular Dystrophy, Confirmatory Trial, Phase III, RACER53 Study, FDA Approval

Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success

1 year ago talkbio0Tagged China, CLEAR-1, Clinical Research, Dental Plaque, Innovent, interleukin-23, picankibart, Psoriasis, regulatory

Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study

Palleos Healthcare and OCT Global Unite to Form Comprehensive European Contract Research Organization ###

1 year ago talkbio0Tagged Clinical Research, Contract Research Organization, CRO, European (ethnic group), Generalized, Merger, Palleos Healthcare

Palleos Healthcare, OCT Global, European CRO, Merger, Clinical Research, Contract Research Organization

Novartis Achieves Success in Two Phase III Trials for Rare Kidney Diseases, Eyes Regulatory Submissions

1 year ago1 year ago talkbio0Tagged C3 glomerulopathy, IGA Glomerulonephritis, Infrequent, Novartis, Phase 3 Clinical Trials, regulatory, submissions

Novartis, Phase III trials, Rare kidney diseases, IgA nephropathy, C3 glomerulopathy, Regulatory submissions

NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment

1 year ago talkbio0Tagged Approved, Clinical Research, Confirmatory Trial, Muscular Dystrophy, Duchenne, nanosecond, Pharma, Phase 3 Clinical Trials, RACER53, United States Food and Drug Administration, Viltepso

Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment

J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks

1 year ago talkbio0Tagged Actinium, Cancer Therapeutic Procedure, Cessation of life, Clinical Trials, dosing, Drug Development, Flexible, J&J, Johnson & Johnson, Malignant neoplasm of prostate

J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.